Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma

Cancer Research

Volumn 58, Issue 19, 1998, Pages 4324-4332

  Henderikx, Paula ^a   Kandilogiannaki, Maria ^b   Petrarca, Claudia ^a,c   Von Mensdorff Pouilly, Silvia ^d   Hilgers, Joseph H M ^d   Krambovitis, Elias ^b   Arends, Jan Willem ^a   Hoogenboom, Hennie R ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b INSTITUTE OF MOLECULAR BIOLOGY AND BIOTECHNOLOGY   (Greece)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

ANTIBODY SPECIFICITY; ARTICLE; BREAST ADENOCARCINOMA; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOLECULAR CLONING; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; TANDEM REPEAT;

ADENOCARCINOMA; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; BINDING SITES, ANTIBODY; BREAST NEOPLASMS; CA-15-3 ANTIGEN; COLONIC NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIAL CELLS; EPITOPES; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOHISTOCHEMISTRY; MICE; MOLECULAR SEQUENCE DATA; OVARIAN NEOPLASMS; PEPTIDE FRAGMENTS; PEPTIDE LIBRARY; SENSITIVITY AND SPECIFICITY;

EID: 0032189703     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Kohler, G., and Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (Lond.), 256: 495-497, 1975.
2. Hilkens, J., Buijs, F., Hilgers, J., Hageman, P., Calafat, J., Sonnenberg, A., and van der Valk, M. Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int. J. Cancer, 34: 197-206, 1984.
3. Hilkens, J., Ligtenberg, M. J., Vos, H. L., and Litvinov, S. V. Cell membrane-associated mucins and their adhesion-modulating property. Trends Biochem. Sci., 17: 359-363, 1992.
4. Zotter, S., Hageman, P. C., Lossnitzer, A., van den Tweel, J., Hilkens, J., Mooi, W. J., and Hilgers, J. Monoclonal antibodies to epithelial sialomucins recognize epitopes at different cellular sites in adenolymphomas of the parotid gland. Int. J. Cancer Suppl., 3: 38-44, 1988.
5. Karlsson, S., Swallow, D. M., Griffiths, B., Corney, G., Hopkinson, D. A., Dawnay, A., and Cartron, J. P. A genetic polymorphism of a human urinary mucin. Ann. Hum. Genet., 47: 263-269, 1983.
6. Swallow, D. M., Griffiths, B., Bramwell, M., Wiseman, G., and Burchell, J. Detection of the urinary "PUM" polymorphism by the tumour-binding monoclonal antibodies Ca1, Ca2, Ca3, HMFG1, and HMFG2. Dis. Markers, 4: 247-254, 1986.
7. Gendler, S., Taylor-Papadimitriou, J., Duhig, T., Rothbard, J., and Burchell, J. A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J. Biol. Chem., 263: 12820-12823, 1988.
8. Gendler, S. J., Lancaster, C. A., Taylor-Papadimitriou, J., Duhig, T., Peat, N., Burchell, J., Pemberton, L., Lalani, E. N., and Wilson, D. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J. Biol. Chem., 205: 15286-15293, 1990.
9. Berruti, A., Tampellini, M., Torta, M., Buniva, T., Gorzegno, G., and Dogliotti, L. Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of disease. Eur. J. Cancer, 30A: 2082-2084, 1994.
10. Martoni, A., Zamagni, C., Bellanova, B., Zanichelli, L., Vecchi, F., Cacciari, N., Strocchi, E., and Pannuti, F. CEA, MCA, CA 15.3 and CA 549 and their combinations in expressing and monitoring metastatic breast cancer: a prospective comparative study. Eur. J. Cancer, 31A: 1615-1621, 1995.
11. Barratt-Boyes, S. Making the most of mucin: a novel target for tumor immunotherapy. Cancer Immunol. Immunother., 43: 142-151, 1996.
12. Graham, R. A., Burchell, J. M., and Taylor-Papadimitriou, J. The polymorphic epithelial mucin: potential as an immunogen for a cancer vaccine. Cancer Immunol. Immunother., 42: 71-80, 1996.
13. Apostolopoulos, V., and McKenzie, I. F. Cellular mucins: targets for immunotherapy. Crit. Rev. Immunol., 14: 293-309, 1994.
14. Burchell, J., Gendler, S., Taylor-Papadimitriou, J., Girling, A., Lewis, A., Millis, R., and Lamport, D. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res., 47: 5476-5482, 1987.
15. Burchell, J., and Taylor-Papadimitriou, J. Effect of modification of carbohydrate side chains on the reactivity of antibodies with core-protein epitopes of the MUC1 gene product. Epithelial Cell Biol., 2: 155-162, 1993.
16. Fontenot, J. D., Tjandra, N., Bu, D., Ho, C., Montelaro, R. C., and Finn, O. J. Biophysical characterization of one-, two-, and three-tandem repeats of human mucin (muc-1) protein core. Cancer Res., 53: 5386-5394, 1993.
17. Hilgers, J., von Mensdorff-Pouilly, S., Verstraeten, A. A., and Kenemans, P. Quantitation of polymorphic epithelial mucin: a challenge for biochemists and immunologists. Scand. J. Clin. Lab. Invest. Suppl., 221: 81-86, 1995.
18. Maraveyas, A., Stafford, N., Rowlinson-Busza, G., Stewart, J. S., and Epenetos, A. A. Pharmacokinetics, biodistribution, and dosimetry of specific and control radiolabeled monoclonal antibodies in patients with primary head and neck squamous cell carcinoma. Cancer Res., 55: 1060-1069, 1995.
19. van Hof, A. C., Molthoff, C. F., Davies, Q., Perkins, A. C., Verheijen, R. H., Kenemans, P., den Hollander, W., Wilhelm, A. J., Baker, T. S., Sopwith, M., Frier, M., Symonds, E. M., and Roos, J. C. Biodistribution of (111)indium-labeled engineered human antibody CTMO1 in ovarian cancer patients: influence of protein dose. Cancer Res., 56: 5179-5185, 1996.
20. Granowska, M., Britton, K. E., Mather, S. J., Lowe, D. G., Ellison, D., Bomanji, J., Burchell, J., Taylor-Papadimitriou, J., Hudson, C. R., and Shepherd, J. H. Radioimmunoscintigraphy with technetium-99m-labelled monoclonal antibody, SM3, in gynaecological cancer. Eur. J. Nucl. Med., 20: 483-489, 1993.
21. Kunkler, R. B., Bishop, M. C., Green, D. J., Pimm, M. V., Price, M. R., and Frier, M. Targeting of bladder cancer with monoclonal antibody NCRC48-a possible approach for intravesical therapy. Br. J. Urol., 76: 81-86, 1995.
22. 131I-labelled monoclonal antibodies HMFG2 and HMFG1 F(ab′)2 versus abdominal CT scan in the detection of residual disease in ovarian cancer patients. Int. J. Cancer Suppl., 3: 83-88, 1988.
23. 131I-labelled HMFG2 and HMFG1 F(ab′)2 in the pre-operative detection of clinical and subclinical lymph node metastases in breast cancer patients. Int. J. Cancer. Suppl., 3: 89-95, 1988.
24. Epenetos, A. A., Hooker, G., Krausz, T., Snook, D., Bodmer, W. F., and Taylor-Papadimitriou, J. Antibody-guided irradiation of malignant ascites in ovarian cancer: a new therapeutic method possessing specificity against cancer cells. Obstet. Gynecol., 68: 71S-74S, 1986.
25. DeNardo, S. J., Kramer, E. L., O'Donnell, R. T., Richman, C. M., Salako, Q. A., Shen, S., Noz, M., Glenn, S. D., Ceriani, R. L., and DeNardo, G. L. Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial. J. Nucl. Med., 38: 1180-1185, 1997.
26. Baker, T. S., Bose, C. C., Caskey-Finney, H. M., King, D. J., Lawson, A. D., Lyons, A., Mountain, A., Owens, R. J., Rolfe, M. R., Sehdev, M., Yarranton, G. T., and Adair, J. R. Humanization of an anti-mucin antibody for breast and ovarian cancer therapy. Adv. Exp. Med. Biol., 353: 61-82, 1994.
27. Couto, J. R., Padlan, E. A., Blank, E. W., Peterson, J. A., and Ceriani, R. L. Humanization of KC4G3, an anti-human carcinoma antibody. Hybridoma, 13: 21S-219, 1994.
28. Fiorentini, S., Matczak, E., Gallo, R. C., Reitz, M. S., Keydar, I., and Watkins, B. A. Humanization of an antibody recognizing a breast cancer specific epitope by CDR-grafting. Immunotechnology, 3: 45-59, 1997.
29. Couto, J. R., Christian, R. B., Peterson, J. A., and Ceriani, R. L. Designing human consensus antibodies with minimal positional templates. Cancer Res., 55: 5973s-5977s, 1995.
30. Winter, G., Griffiths, A. D., Hawkins, R. E., and Hoogenboom, H. R. Making antibody by phage display technology. Annu. Rev. Immunol., 12: 433-455, 1994.
31. Marks, J. D., Hoogenboom, H. R., Bonnert, T. P., McCafferty, J., Griffiths, A. D., and Winter, G. By-passing immunization: human antibodies from V-gene libraries displayed on phage. J. Mol. Biol., 222: 581-597, 1991.
32. Griffiths, A. D., and Hoogenboom, H. R. Building an in vitro immune system: human antibodies from phage display libraries. In: M. Clark (ed.) Protein Engineering of Antibody for Prophylactic and Therapeutic Applications in Man, pp. 45-64. Norwich: Academic Titles, 1993.
33. Vaughan, T. P., Williams A. W., Pritchard, K., Osbourn, J. K., Pope, A. R., Earnshaw, J. C., McCafferty, J., Hodits, R. A., Wilton, J., and Johnson, K. S. Human antibody with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat. Biotechnol., 14: 309-314, 1996.
34. Osbourn, J. K., Field, A., Wilton, J., Derbyshire, E., Earnshaw, J. C., Jones, P. T., Alien, D., and McCafferty, J. Generation of a panel of related human scFv antibodies with high affinities for human CEA. Immunotechnology, 2: 181-196, 1996.
35. de Haard, H., Henderikx, P., and Hoogenboom, H. R. Creating and engineering human antibodies for immunotherapy. Adv. Drug Del. Rev., 31: 5-31, 1998.
36. Krambovitis, E., Xatzidakis, G., and Barlos, K. Preparation of MUC-1 oligomers using an improved convergent solid-phase peptide synthesis. J. Biol. Chem., 273: 10874-10879, 1998.
37. Hanisch, F. G., Stadie, T. R., Deutzmann, F., and Peter-Katalinic, J. MUC1 glycoforms in breast cancer-cell line T47D as a model for carcinoma-associated alterations of O-glycosylation. Eur. J. Biochem., 236: 318-327, 1996.
38. Hawkins, R. E., Russell, S. J., and Winter, G. Selection of phage antibodies by binding affinity. Mimicking affinity maturation. J. Mol. Biol., 226: 889-896, 1992.
39. Clackson, T., Hoogenboom, H. R., Griffiths, A. D., and Winter, G. Making antibody fragments using phage display libraries. Nature (Lond.), 352: 624-628, 1991.
40. Gussow, D., and Clackson, T. Direct clone characterization from plaques and colonies by the polymerase chain reaction. Nucleic Acids Res., 17: 4000, 1989.
41. Polymenis, M., and Stollar, B. D. Single-chain anti-DNA FV. Methods Mol. Biol., 51: 265-279, 1995.
42. Chan, S., Gabra, H., Hill, F., Evan, G., and Sikora, K. A novel tumour marker related to the c-myc oncogene product. Mol. Cell Probes, 1: 73-82, 1987.
43. von Mensdorff-Pouilly, S., Gourevitch, M., Kenemans, P., Verstraeten, A., van Kamp, G., Kok, A., van Uffelen, K., Snijdewint, F., Paul, M., Meijer, S., and Hilgers, J. An enzyme-linked immunosorbent assay for the measurement of circulating antibodies to polymorphic epithelial mucin (MUC1). Tumor Biol., 19: 186-195, 1998.
44. Schol, D. J., Meulenbroek, M. F., Snijdewint, F. G., von Mensdorff-Pouilly, S., Verstraeten, R. A., Murakami, F., Kenemans, P., and Hilgers, J. "Epitope fingerprinting" using overlapping 20-mer peptides of the MUC1 tandem repeat sequence. Tumour Biol., 19 (Suppl. 1): 35-45, 1998.
45. Cao, Y., Karsten, U., and Hilgers, J. Immunohistochemical characterization of a panel of 56 antibodies with normal human small intestine, colon, and breast tissues. Tumour Biol., 19 (Suppl. 1): 88-99, 1998.
46. Acres, R. B., Hareuveni, M., Balloul, J. M., and Kieny, M. P. Vaccinia virus MUC1 immunization of mice: immune response and protection against the growth of murine tumors bearing the MUC1 antigen. J. Immunother., 14: 136-143, 1993.
47. Coligan, J. E., Kruisbeek, A. M., Margulies, D. H., Shevach, E. M., and Strober, W. Preparation of cells and reagents for flow cytometry. Vol. 1, p. 5.3. New York: John Wiley & Sons, 1996.
48. Burchell J., Taylor-Papadimitriou, J., Boshell, M., Gendler, S., and Duhig, T. A short sequence, within the amino acid tandem repeat of a cancer-associated mucin, contains immunodominant epitopes. Int. J. Cancer, 44: 691-696, 1989.
49. Xing, P. X., Prenzoska, J., Quelch, K., and McKenzie, I. F. Second generation anti-MUC1 peptide monoclonal antibodies. Cancer Res., 52: 2310-2317, 1992.
50. Blockzjil, A., Nilsson, K., and Nilsson, O. Epitope characterization of MUC1 antibodies. Tumour Biol., 19 (Suppl. 1): 46-56, 1998.
51. Ciborowski, P., Konitzki, W. M., Blander, J. M., and Finn, O. J. Screening of anti-MUC1 antibodies for reactivity with native (ascites) and recombinant (baculo-virus) MUC1 and for blocking MUC1 specific cytotoxic T-lymphocytes. Tumour Biol., 19 (Suppl. 1): 147-151, 1998.
52. Reis, C. A., Hassan, H., Bennett, E. P., and Clausen, H. Characterization of a panel of monoclonal antibodies using GalNAc glycosylated peptides and recombinant MUC1. Tumour Biol., 19 (Suppl. 1): 127-133, 1998.
53. Price, M. R., Rye, P. D., Petrakou, E., Murray, A., Brady, K., Imai, S., Haga, S., Kiyozuka, Y., Schol, D., Meulenbroek, M. F., Snijdewint, F. G., von Mensdorff-Pouilly, S., Verstraeten, R. A., Kenemans, P., Blockzjil, A., Nilsson, K., Nilsson, O., Reddish, M., Suresh, M. R., Koganty, R. R., Fortier, S., Baronic, L., Berg, A., Longenecker, M. B., Hilkens, J., Boer, M., Karanikis, V., McKenzie, I. F., Galanina, O. E., Simeoni, L. A., Ter-Grigoryan, A. G., Belyanchikov, I. M., Bovin, N. V., Cao, Y., Karsten, U., Dai, J., Allard, W. J., Davis, G., Yeung, K. K., Hanisch, F-G., Lloyd, K. O., Kudryashov, V., Sikut, S., Sikut, A., Zhang, K., Baeckstrom, D., Hansson, G. C., Bennett, E. P., Claussen, H., Norum, L., Varaas, T., Kierulf, B., Nustad, K., Ciborowski, P., Konitzki, W. M., Magarian-Blander, J., Finn, O. J., and Hilgers, J. Summary report on the ISOBM TD-4 Workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. Tumour Biol., 19 (Suppl. 1): 1-20, 1998.
54. Briggs, S., Price, M. R., and Tendier, S. J. Fine specificity of antibody recognition of carcinoma-associated epithelial mucins: antibody binding to synthetic peptide epitopes. Eur. J. Cancer, 29A: 230-237, 1993.
55. Kotera, Y., Fontenot, J. D., Pecher, G., Metzgar, R. S., and Finn, O. J. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res., 54: 2856-2860, 1994.
56. Petrarca, C., Rughetti, A., Rahimi, H., D'Agostini, F., Turchi, V., Apollonj Ghetti, C., Scambia, G., Frati, L., and Nuti, M. Human antibodies against the polymorphic epithelial mucin in ovarian cancer patients recognise a novel sequence in the tandem repeat region. Eur. J. Cancer, 32A: 2155-2163, 1996.
57. Karanikas, V., Hwang, L. A., Pearson, J., Ong, C. S., Apostolopoulos, V., Vaughan, H., Xing, P. X., Jamieson, G., Pietersz, G., Tait, B., Broadbent, R., Thynne, G., and McKenzie, I. F. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J. Clin. Invest., 100: 2783-2792, 1997.
58. Griffiths, A. D., Malmqvist, M., Marks, J. D., Bye, J. M., Embleton, M. J., McCafferty, J., Baier M., Holliger, K. P., Gorick, B. D., Hughes, J. N., Hoogenboom, H. R., and Winter, G. Human anti-self antibodies with high specificity from phage display libraries. EMBO J., 12: 725-734, 1993.
59. Williams, S. C., and Winter, G. Cloning and sequencing of human immunoglobulin V lambda gene segments. Eur. J. Immunol., 23: 1456-1461, 1993.
60. Lloyd, K. O., Burchell, J., Kudryashov, V., Yin, B. W. T., and Taylor-Papadimitriou, J. Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines. Demonstration of simpler and fewer glycan chains in tumor cells. J. Biol. Chem., 271: 33325-33334, 1996.
61. Girling, A., Bartkova, J., Burchell, J., Gendler, S., Gillett, C., and Taylor-Papadimitriou, J. A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM-3 is selectively exposed in a range of primary carcinomas. Int. J. Cancer. 43: 1072-1076, 1989.
62. Peterson, J. A., Blank, E. W., and Ceriani, R. L. Effect of multiple, repeated doses of radioimmunotherapy on target antigen expression (breast MUC-1 mucin) in breast carcinomas. Cancer Res., 57: 1103-1108, 1997.
63. Litvinov, S. V., and Hilkens, J. The epithelial sialomucin, episialin, is sialylated during recycling. J. Biol. Chem., 268: 21364-21371, 1993.
64. Pietersz, G. A., Wenjun, L., Krauer, K., Baker, T., Wreschner, D., and McKenzie, I. F. Comparison of the biological properties of two anti-mucin-1 antibodies prepared for imaging and therapy. Cancer Immunol. Immunother., 44: 323-328, 1997.
65. Agrawal, B., Krantz, M. J., Reddish, M. A., and Longenecker, B. M. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat. Med., 4: 43-49, 1998.